DOCSLIB.ORG

SYNALGOS-DC (Aspirin, Caffeine, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use -----------------------DOSAGE AND ADMINISTRATION----------------------- SYNALGOS®-DC safely and effectively. See full prescribing information for • Use the lowest effective dose for the shortest duration consistent with SYNALGOS®-DC. individual patient treatment goals. (2.1) • Individualize dosing based on the severity of pain, patient response, prior SYNALGOS®-DC (aspirin, caffeine, and dihydrocodeine bitartrate) capsules, analgesic experience, and risk factors for addiction, abuse, and misuse. (2.1) for oral use, CIII • Initiate treatment with two capsules orally every 4 hours as needed for pain. Initial U.S. Approval: 1958 (2.2) • Administer SYNALGOS-DC with food or a full glass of water to minimize WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE­ gastrointestinal (GI) distress. (2.1) THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL • Do not stop SYNALGOS-DC abruptly in a physically dependent patient. INGESTION; ULTRA-RAPID METABOLISM OF DIHYDROCODEINE (2.4) AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS Capsules: 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine AFFECTING CYTOCHROME P450 ISOENZYMES; and RISKS FROM (3) CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS ------------------------------CONTRAINDICATIONS------------------------------­ • Children younger than 12 years of age (4) See full prescribing information for complete boxed warning. • Post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (4) • SYNALGOS-DC exposes users to risks of addiction, abuse, and misuse, • Significant respiratory depression (4) which can lead to overdose and death. Assess patient's risk before • Acute or severe bronchial asthma in an unmonitored setting or in absence of prescribing and monitor regularly for these behaviors and conditions. resuscitative equipment (4) (5.1) • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs • Serious, life-threatening, or fatal respiratory depression may occur. within the last 14 days (4) Monitor closely, especially upon initiation or following a dose increase. • Known or suspected gastrointestinal obstruction, including paralytic ileus (4) (5.2) • Hypersensitivity to dihydrocodeine, codeine, or aspirin (4) • Accidental ingestion of SYNALGOS-DC, especially by children, can • Hemophilia (4) result in a fatal overdose of dihydrocodeine. (5.2) • Reye’s Syndrome (4) • Life-threatening respiratory depression and death have occurred in • Known allergy to NSAIDs (4) children who received codeine; most cases followed tonsillectomy • Syndrome of asthma, rhinitis, and nasal polyps (4) and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. ------------------------WARNINGS AND PRECAUTIONS----------------------­ (5.3) SYNALGOS-DC is contraindicated in children younger than 12 • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary years of age and in children younger than 18 years of age following Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, tonsillectomy and/or adenoidectomy. (4) Avoid the use of SYNALGOS­ particularly during initiation and titration. (5.7) DC in adolescents 12 to 18 years of age who have other risk factors that • Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of may increase their sensitivity to the respiratory depressant effects of corticosteroids, and wean patient off of the opioid. (5.9) dihydrocodeine. • Severe Hypotension: Monitor during dosage initiation and titration. Avoid • Prolonged use of SYNALGOS-DC during pregnancy can result in use of SYNALGOS-DC in patients with circulatory shock. (5.10) neonatal opioid withdrawal syndrome, which may be life-threatening if • Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, not recognized and treated. If prolonged opioid use is required in a Head Injury, or Impaired Consciousness: Monitor for sedation and pregnant woman, advise the patient of the risk of neonatal opioid respiratory depression. Avoid use of SYNALGOS-DC in patients with withdrawal syndrome and ensure that appropriate treatment will be impaired consciousness or coma. (5.11) available. (5.4) • Risks of Use in Patients with Gastrointestinal Conditions Including Peptic • The effects of concomitant use or discontinuation of cytochrome P450 Ulcer Disease: Aspirin can cause an increased risk of serious gastrointestinal 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with dihydrocodeine (GI) adverse events including bleeding, ulceration, and perforation of the are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or stomach or intestines, which can be fatal. These events can occur at any time 2D6 inhibitors with SYNALGOS-DC requires careful consideration of during use and without warning symptoms. Elderly patients and patients the effects on the parent drug, dihydrocodeine, and the active with a prior history of peptic ulcer disease and/or GI bleeding are at greater metabolite, dihydromorphine. (5.5), (7) risk for serious GI events. (5.12) • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in -------------------------------ADVERSE REACTIONS-----------------------------­ profound sedation, respiratory depression, coma, and death. Reserve Most common adverse reactions were lightheadedness, dizziness, drowsiness, concomitant prescribing for use in patients for whom alternative sedation, nausea, vomiting, constipation, pruritus, and skin reactions. (6) treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of To report SUSPECTED ADVERSE REACTIONS, contact Sun respiratory depression and sedation. (5.6), (7) Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ---------------------------RECENT MAJOR CHANGES--------------------------­ Boxed Warning 08/2017 -------------------------------DRUG INTERACTIONS-----------------------------­ Indications and Usage (1) 12/2016 • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Dosage and Administration (2) 08/2017 Discontinue SYNALGOS-DC if serotonin syndrome is suspected. (7) Contraindications (4) 08/2017 • Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use Warnings and Precautions (5) 08/2017 with SYNALGOS-DC because they may reduce analgesic effect of SYNALGOS-DC or precipitate withdrawal symptoms. (7) ----------------------------INDICATIONS AND USAGE--------------------------­ SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a ------------------------USE IN SPECIFIC POPULATIONS----------------------­ nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is • Pregnancy: May cause fetal harm. Use of aspirin, including SYNALGOS­ indicated for the management of pain severe enough to require an opioid analgesic DC, during the third trimester of pregnancy increases the risk of premature and for which alternative treatments are inadequate. (1) closure of the fetal ductus arteriosus. (8.1) • Lactation: Breastfeeding not recommended. (8.2) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at See 17 for PATIENT COUNSELING INFORMATION and Medication recommended doses, reserve SYNALGOS-DC for use in patients for whom Guide. alternative treatment options (e.g., non-opioid analgesics): Revised: 8/2017 • Have not been tolerated, or are not expected to be tolerated, • Have not provided adequate analgesia, or are not expected to provide adequate analgesia Reference ID: 4145172 FULL PRESCRIBING INFORMATION: CONTENTS* 5.13 Increased Risk of Seizures in Patients with Convulsive or Seizure Disorders WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING 5.14 Withdrawal RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA­ 5.15 Risks of Driving and Operating Machinery RAPID METABOLISM OF DIHYDROCODEINE AND OTHER RISK 5.16 Coagulation Abnormalities and Bleeding Risks FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN 5.17 Reye’s Syndrome CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; 5.18 Allergy INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 5.19 Renal Toxicity and Hyperkalemia ISOENZYMES; and RISKS FROM CONCOMITANT USE WITH 5.20 Premature Closure of Fetal Ductus Arteriosus BENZODIAZEPINES OR OTHER CNS DEPRESSANTS 6 ADVERSE REACTIONS 7 DRUG INTERACTIONS 1 INDICATIONS AND USAGE 8 USE IN SPECIFIC POPULATIONS 2 DOSAGE AND ADMINISTRATION 8.1 Pregnancy 2.1 Important Dosage and Administration Instructions 8.2 Lactation 2.2 Initial Dosage 8.3 Females and Males of Reproductive Potential 2.3 Titration and Maintenance of Therapy 8.4 Pediatric Use 2.4 Discontinuation of SYNALGOS-DC 8.5 Geriatric Use 3 DOSAGE FORMS AND STRENGTHS 8.6 Hepatic Impairment 4 CONTRAINDICATIONS 8.7 Renal Impairment 5 WARNINGS AND PRECAUTIONS 9 DRUG ABUSE AND DEPENDENCE 5.1 Addiction, Abuse, and Misuse 9.1 Controlled Substance 5.2 Life-Threatening Respiratory Depression 9.2 Abuse 5.3 Ultra-Rapid Metabolism of Dihydrocodeine and Other Risk Factors for 9.3 Dependence Life-Threatening Respiratory Depression in Children
Recommended publications
  • Opioid Receptorsreceptors

    Opioid Receptorsreceptors

    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products

    Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products

    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
  • Picquestion of the Week:1/09/12

    Picquestion of the Week:1/09/12

    Grand Teton, Wyoming USA PIC QUESTION OF THE WEEK: 1/09/12 Q: Can fentanyl be prescribed for a patient allergic to codeine? A: Opioid analgesics are among the most commonly prescribed drugs in the United States. True allergic reactions to opioid analgesics are extremely rare, dependent upon antibody (usually IgE/IgG), and triggered by histamine and other mediators. Immediate reactions (e.g. anaphylaxis) are associated with contraction of smooth muscle, vasodilation, increased mucous secretion, and enhanced vasopermeability. More frequently, opioids such as morphine and codeine cause direct release of histamine from mast cells. These reactions are considered idiosyncratic, independent of antibody, and based on individual patient susceptibility. Direct release of histamine is the most common mechanism for the development of urticaria, pruritus, etc. in patients receiving natural opioids such as morphine and codeine. Opioid analgesics are typically classified according to the source of the chemical or the presence of structurally related groups (see table). In general, the risk of cross-reactivity is thought to be less likely among agents from a different source or structural class. If a reaction to morphine or codeine is severe in nature, substituting a synthetic or semi-synthetic agent or a structurally dissimilar compound appears to reduce the risk of cross-reactivity. It should be noted that although tramadol is classified as a synthetic opioid derivative, there have been cases of severe hypersensitivity reactions associated with its use. These cases have occurred in patients with and without a history of allergic reactions to opiates. Thus tramadol would probably not a good first alternative in a patient with a history of a severe reaction to this group of drugs.
  • The Main Tea Eta a El Mattitauli Mali Malta

    The Main Tea Eta a El Mattitauli Mali Malta

    THE MAIN TEA ETA USA 20180169172A1EL MATTITAULI MALI MALTA ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0169172 A1 Kariman (43 ) Pub . Date : Jun . 21 , 2018 ( 54 ) COMPOUND AND METHOD FOR A61K 31/ 437 ( 2006 .01 ) REDUCING APPETITE , FATIGUE AND PAIN A61K 9 / 48 (2006 .01 ) (52 ) U . S . CI. (71 ) Applicant : Alexander Kariman , Rockville , MD CPC . .. .. .. .. A61K 36 / 74 (2013 .01 ) ; A61K 9 / 4825 (US ) (2013 . 01 ) ; A61K 31/ 437 ( 2013 . 01 ) ; A61K ( 72 ) Inventor: Alexander Kariman , Rockville , MD 31/ 4375 (2013 .01 ) (US ) ( 57 ) ABSTRACT The disclosed invention generally relates to pharmaceutical (21 ) Appl . No. : 15 /898 , 232 and nutraceutical compounds and methods for reducing appetite , muscle fatigue and spasticity , enhancing athletic ( 22 ) Filed : Feb . 16 , 2018 performance , and treating pain associated with cancer, trauma , medical procedure , and neurological diseases and Publication Classification disorders in subjects in need thereof. The disclosed inven ( 51 ) Int. Ci. tion further relates to Kratom compounds where said com A61K 36 / 74 ( 2006 .01 ) pound contains at least some pharmacologically inactive A61K 31/ 4375 ( 2006 .01 ) component. pronuPatent Applicationolan Publication manu saJun . decor21, 2018 deSheet les 1 of 5 US 2018 /0169172 A1 reta Mitragynine 7 -OM - nitragynine *** * *momoda W . 00 . Paynantheine Speciogynine **** * * * ! 1000 co Speclociliatine Corynartheidine Figure 1 Patent Application Publication Jun . 21, 2018 Sheet 2 of 5 US 2018 /0169172 A1
  • 1 Impact of Opioid Agonists on Mental Health in Substitution

    1 Impact of Opioid Agonists on Mental Health in Substitution

    Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trials Supplementary Table 1_ Specific search strategy for each database The following general combination of search terms, Boolean operators, and search fields were used where “*” means that any extension of that word would be considered: Title field [opium OR opiate* OR opioid OR heroin OR medication assisted OR substitution treatment OR maintenance treatment OR methadone OR levomethadone OR buprenorphine OR suboxone OR (morphine AND slow) OR diamorphine OR diacetylmorphine OR dihydrocodeine OR hydromorphone OR opium tincture OR tincture of opium OR methadol OR methadyl OR levomethadyl] AND Title/Abstract field [trial* OR random* OR placebo] AND All fields [depress* OR anxiety OR mental] Wherever this exact combination was not possible, a more inclusive version of the search strategy was considered. Database Search Strategy Ovid for EBM Reviews - Cochrane Central Register of (opium or opiate$ or opioid or heroin or medication Controlled Trials August 2018; Embase 1974 to assisted or substitution treatment or maintenance September 07, 2018; MEDLINE(R) and Epub Ahead treatment or methadone or levomethadone or of Print, In-Process & Other Non-Indexed Citations buprenorphine or suboxone or (morphine and slow) or and Daily 1946 to September 07, 2018 diamorphine or diacetylmorphine or dihydrocodeine or hydromorphone or opium tincture or tincture of opium or methadol or methadyl
  • Methadone & EDDP by Liquid/Liquid Extraction and Gas

    Methadone & EDDP by Liquid/Liquid Extraction and Gas

    OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK METHADONE & EDDP BY LIQUID/LIQUID EXTRACTION AND GAS CHROMATOGRAPHY/MASS SPECTROMETRY (SELECTIVE ION MONITORING) PRINCIPLE Methadone (Symoron, Dolophine, Amidone, Methadose, Physeptone, Heptadon and many other names) is a synthetic opioid developed in Germany in 1937. It is used medically as an analgesic and also as a maintenance anti-addictive and reductive preparation for use by patients with opioid dependence. Because it is structurally an acyclic analog of morphine, methadone also acts upon the same opioid receptors, and thus has many of the same effects. Because of its long duration of action, strong analgesic effects, methadone is also used in managing severe chronic pain. Eli Lilly and Company introduced methadone into the United States in 1947. The abuse of methadone results in approximately 5,000 overdose deaths per year in the United States. Methadone is mainly used in the treatment of opioid dependence. It has cross-tolerance with other opioids including morphine, codeine and heroin, and offers very similar effects but with a longer duration. Oral doses of methadone can stabilize patients by mitigating opioid withdrawal syndrome or making it more tolerable. Higher doses can block the euphoric effects of heroin and morphine. Methadone is produced and distributed by a number of pharmaceutical companies. The racemic hydrochloride is the only form available in most countries, such as the Netherlands, Belgium, France and in the United States (as of March 2008). The dextrorotary enantiomer of methadone, dextromethadone, is an NMDA antagonist rather than an opiate agonist. As a result, methadone medications used for opiate addiction occasionally will contain only levomethadone, the levorotary enantiomer.
  • List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of narcotic substances circulation of which is restricted in Uzbekistan 1. 2C-B(4-bromo-2,5-dimethoxyphenethylamine) 2. 3-methylfentanyl 3. 3-methylthiofentanyl 4. 3-Monoacetylmorphine 5. 4-methylaminorex 6. 6- Monoacetylmorphine 7. Acetorphine 8. Acetyl Dihydrocodeine 9. Acetyl-alfametilfentanil 10. Acetylated opium 11. Acetylcodeine 12. Acetylmethadol 13. Alfametadol 14. Alfatsetilmetadol 15. all fungi that contain Psilocine and Psilocybine 16. Allylprodine 17. Alpha Methylfentanyl 18. Alpha Metiltiofentanil 19. Alphaprodine 20. Anileridin 21. Benzethidine 22. Benzylmorphine 23. Betacetylmethadol 24. Betahydroxyfentanyl 25. Betameprodine 26. Betamethadol 27. Betaprodine 28. Bezitramide 29. Cannabis oil (hashish oil) 30. Cannabis, marihuana 31. Cathine ((+)-norpseudoephedrine) 32. Cathinone (l-alpha-aminopropiofenon) 33. Clonitazene 34. Cocaine 35. Codoxime 36. d- Methadone 37. DB [L-(3,4 - methylenedioxyphenyl) -2 butanamine] 38. Desmethylprodine; MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 39. Desomorphine 40. DET (N,N-diethyltryptamine) 41. Dexamphetamine 42. Diampromide 43. Diethyl phosphate 44. Diethylthiambutene 45. Dihydromorphine 46. Dimenoxadol 47. Dimepheptanol 48. Dimethylthiambutene 49. Dioxaphetyl butyrate 50. Diphenoxine 51. Dipipanone 52. DMA (2,5-dimethoxyamphetamine) 53. DMGP (dimetilgeptilpiran) 54. DMT (dimethyltryptamine) 55. DOB (d, L-2,5-dimethoxy-4-bromo-amphetamine) 56. DOC (d, L-2,5-dimethoxy-4-chloro-amphetamine) 57. DOET (2,5-dimethoxy-4-ethylamphetamine) 58. Drotebanol 59. Ecgonine 60. Ephedrone 61. Ethylmethylthiambutene 62. Eticyclidine 63. Etonitazene 64. Etorphine 65. Etoxeridine 66. Etryptamine 67. Furethidine 68. Hashish (Anasha, cannabis resin) 69. Heroin (Diacetylmorphine) 70. Hydrocodone 71. Hydrocodone phosphate 72. Hydromorphinol 73. Hydromorphone 74. Isomethadone 75. Ketobemidone 76. Khat 77. L- Methadone 78. Levomethorphan 79. Levomoramide 80. Levophenacylmorphan 81. Levorphanol 82. Lysergic acid and its preparations, that include d-Lysergide (LSD, LSD-25) 83.
  • Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)

    Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)

    NATIONAL DEFENSE RESEARCH INSTITUTE Effects of Medication- Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes A Systematic Review Margaret A. Maglione, Laura Raaen, Christine Chen, Gulrez Shah Azhar, Nima Shahidinia, Mimi Shen, Ervant J. Maksabedian Hernandez, Roberta M. Shanman, Susanne Hempel Prepared for the Office of the Secretary of Defense Approved for public release; distribution unlimited For more information on this publication, visit www.rand.org/t/RR2108 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation R® is a registered trademark. Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Over the past two decades, the U.S. Department of Defense (DoD) has invested unparalleled resources into developing effective treatments for military-related psychological health conditions.
  • Narcotic Drugs Stupefiants Estupefacientes

    Narcotic Drugs Stupefiants Estupefacientes

    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
  • Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity

    Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity

    pharmaceutics Review Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity Junzhi Yang 1, Bianca G. Reilly 2, Thomas P. Davis 1,2 and Patrick T. Ronaldson 1,2,* 1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 1295 N. Martin St., P.O. Box 210207, Tucson, AZ 85721, USA; [email protected] (J.Y.); [email protected] (T.P.D.) 2 Department of Pharmacology, College of Medicine, University of Arizona, 1501 N. Campbell Ave, P.O. Box 245050, Tucson, AZ 85724-5050, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-520-626-2173 Received: 19 September 2018; Accepted: 16 October 2018; Published: 18 October 2018 Abstract: Opioids are highly effective analgesics that have a serious potential for adverse drug reactions and for development of addiction and tolerance. Since the use of opioids has escalated in recent years, it is increasingly important to understand biological mechanisms that can increase the probability of opioid-associated adverse events occurring in patient populations. This is emphasized by the current opioid epidemic in the United States where opioid analgesics are frequently abused and misused. It has been established that the effectiveness of opioids is maximized when these drugs readily access opioid receptors in the central nervous system (CNS). Indeed, opioid delivery to the brain is significantly influenced by the blood-brain barrier (BBB). In particular, ATP-binding cassette (ABC) transporters that are endogenously expressed at the BBB are critical determinants of CNS opioid penetration. In this review, we will discuss current knowledge on the transport of opioid analgesic drugs by ABC transporters at the BBB.
  • F1y3x CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    F1y3x CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
  • Hydromorphone Hydrochloride) CS-II WARNING: DILAUDID ORAL LIQUID and DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS a POTENT SCHEDULE II CONTROLLED OPIOID AGONIST

    Hydromorphone Hydrochloride) CS-II WARNING: DILAUDID ORAL LIQUID and DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS a POTENT SCHEDULE II CONTROLLED OPIOID AGONIST

    DILAUDID® ORAL LIQUID and DILAUDID® TABLETS (hydromorphone hydrochloride) CS-II WARNING: DILAUDID ORAL LIQUID AND DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS, INCLUDING MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE, HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF PRODUCING RESPIRATORY DEPRESSION. ALCOHOL, OTHER OPIOIDS AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVE-HYPNOTICS) POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY DEPRESSION THAT MIGHT RESULT IN DEATH. DESCRIPTION Proprietary name: DILAUDID ORAL LIQUID Established name: hydromorphone hydrochloride Route of administration: ORAL (C38288) Active ingredients (moiety): hydromorphone hydrochloride (hydromorphone) # Strength Form Inactive ingredients 1 5 MILLIGRAM LIQUID purified water, methylparaben, propylparaben, sucrose, glycerin, sodium (C42953) metabisulfite Proprietary name: DILAUDID TABLETS Established name: hydromorphone hydrochloride Route of administration: ORAL (C38288) Active ingredients (moiety): hydromorphone hydrochloride (hydromorphone) # Strength Form Inactive ingredients 1 2 MILLIGRAM TABLET D&C red #30 Lake dye, D&C yellow #10 Lake dye, lactose, magnesium (C42998) stearate, sodium metabisulfite 2 4 MILLIGRAM TABLET D&C yellow #10 Lake dye, lactose, magnesium stearate, sodium metabisulfite (C42998) 3 8 MILLIGRAM TABLET lactose anhydrous, magnesium stearate, sodium metabisulfite (C42998) DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic. The chemical name of DILAUDID (hydromorphone hydrochloride) is 4,5α-epoxy-3- hydroxy-17-methylmorphinan-6-one hydrochloride. The structural formula is: M.W. 321.8 Each 5 mL (1 teaspoon) of DILAUDID ORAL LIQUID contains 5 mg of hydromorphone hydrochloride. In addition, other ingredients include purified water, methylparaben, propylparaben, sucrose, and glycerin. DILAUDID ORAL LIQUID may contain traces of sodium metabisulfite.